Opdivo Makers Challenge Amgen's Biosimilar Ahead of FDA Ruling
Bristol Myers Squibb and Ono are contesting Amgen's biosimilar application as the FDA nears a decision on the first copy of the blockbuster cancer drug.
As the FDA prepares to rule on Amgen's biosimilar version of Opdivo, the drug's original developers, Bristol Myers Squibb and Ono, are actively opposing the application. The two companies are taking steps to defend their oncology blockbuster, which has been a major revenue driver, against the first potential copycat in the U.S. market.
Amgen is aiming to join the initial wave of biosimilars to Opdivo, a treatment used across multiple cancer types. The outcome of the FDA's review will determine whether Amgen can launch a lower-cost alternative, which could reshape the competitive landscape for checkpoint inhibitors.
The source does not provide details on the specific arguments BMS and Ono are making, nor does it indicate a timeline for the FDA's decision. It only notes that the originator partners are not taking the challenge lightly, signaling a high-stakes regulatory battle ahead.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.